Jubilant Pharmova Limited has informed the Exchange about Transcript
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jubilant Pharmova reported Q4 FY2026 revenue of Rs.2,290 Crores (up 19% YoY) but EBITDA margin contracted to 15.7% from 18.4% due to SPECT product supply shortage and under-absorption of costs at CMO Montreal. Full year FY2026 revenue was Rs.8,280 Crores with EBITDA of Rs.1,326 Crores at 15.9% margin. The company expects FY2027 to be a 'story of two halves' with H1 margins temporarily impacted by continued SPECT shortage (~$14 million revenue impact), while H2 margins are guided at 17-18% as Montreal production stabilizes. CDMO Line 3 at Spokane is on track for commercial production in late FY2027 with ~10 products including one major oncology product, targeting peak revenue of $80-90 million earlier than expected. Net debt stands at Rs.1,952 Crores with a commitment to achieve net debt zero by FY2030.
The margin pressure in H1 FY2027 from Montreal supply issues and continued high capex spending suggests near-term earnings may remain constrained. However, the company's Line 3 ramp-up, MIBG NDA filing expected in H2 FY2027, and guidance for H2 margin recovery to 17-18% indicate stronger profitability from H2 FY2027 onwards.